Skip to search formSkip to main contentSkip to account menu

R-138727

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Piperazines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Pharmacokinetics and pharmacodynamics of ticagrelor and prasugrel in healthy male Korean volunteers.
2013
2013
In vitro effects of recombinant activated factor VII on thrombin generation and coagulation following inhibition of platelet procoagulant activity by prasugrel.
2013
2013
P2Y12 Receptor Blockade Augments Glycoprotein IIb‐IIIa Antagonist Inhibition of Platelet Activation, Aggregation, and Procoagulant Activity
Background New antiplatelet agents that provide greater, more consistent inhibition of the platelet ADP receptor P2Y12 may be… 
2011
2011
Modification of the VerifyNow® P2Y12 test BASE channel to accommodate high levels of P2Y12 antagonism
The VerifyNow® P2Y12 (VN-P2Y12) test reports thienopyridine-mediated platelet inhibition relative to a “BASE” channel… 
2009
2009
Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs
Prasugrel and clopidogrel are antiplatelet prodrugs that are converted to their respective active metabolites through thiolactone… 
Review
2009
Review
2009
P2Y12 Inhibitors in Cardiovascular Disease: Focus on Prasugrel
OBJECTIVE To review the literature describing the pharmacology, pharmacokinetic properties, efficacy, and adverse effects of… 
Highly Cited
2008
Highly Cited
2008
Interaction of the active metabolite of prasugrel, R‐138727, with cysteine 97 and cysteine 175 of the human P2Y12 receptor
Summary.  Background: The P2Y12 receptor plays a crucial role in platelet aggregation and is the target of platelet aggregation… 
2007
2007
Stereoselective Metabolism of Prasugrel in Humans Using a Novel Chiral Liquid Chromatography-Tandem Mass Spectrometry Method
A liquid chromatography-tandem mass spectrometry method was developed to chromatographically separate the four stereoisomers of… 
2007
2007
Disposition and metabolic fate of prasugrel in mice, rats, and dogs
The disposition and metabolism of prasugrel, a thienopyridine prodrug and a potent inhibitor of platelet aggregation in vivo… 
Highly Cited
2005
Highly Cited
2005
Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (Prasugrel, LY640315), a novel P2Y12 receptor inhibitor
Summary CS-747 (Prasugrel, LY640315) is a thienopyridine antiplatelet prodrug that is metabolized to the thiol-containing active… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)